+关注
慧敏儿
暂无个人介绍
IP属地：重庆
2
关注
2
粉丝
0
主题
0
勋章
主贴
热门
慧敏儿
06-24
说说你对这篇新闻的看法...
港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4094165147073770,"uuid":"4094165147073770","gmtCreate":1631062759594,"gmtModify":1631062759594,"name":"慧敏儿","pinyin":"hmehuiminer","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":2,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"重庆","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":320190642696248,"gmtCreate":1719201566969,"gmtModify":1719202791986,"author":{"id":"4094165147073770","authorId":"4094165147073770","authorIdStr":"4094165147073770","name":"慧敏儿","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/320190642696248","repostId":"1114706690","repostType":2,"repost":{"id":"1114706690","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1719194593,"share":"https://www.laohu8.com/m/news/1114706690?lang=&edition=full","pubTime":"2024-06-24 10:03","market":"hk","language":"zh","title":"港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保","url":"https://stock-news.laohu8.com/highlight/detail?id=1114706690","media":"老虎资讯综合","summary":"6月24日， 康方生物逆市涨超4%，截至发稿，涨3.93%，报37.05港元。","content":"<html><head></head><body><p>6月24日， <a href=\"https://laohu8.com/S/09926\">康方生物</a> 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fad0d39ba4732de4e269b59b1699349\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。</p><p style=\"text-align: start;\">此外，<a href=\"https://laohu8.com/S/002736\" title=\"国信证券\" class=\"\">国信证券</a>发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-06-24 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>6月24日， <a href=\"https://laohu8.com/S/09926\">康方生物</a> 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fad0d39ba4732de4e269b59b1699349\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。</p><p style=\"text-align: start;\">此外，<a href=\"https://laohu8.com/S/002736\" title=\"国信证券\" class=\"\">国信证券</a>发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"09926":"康方生物"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114706690","content_text":"6月24日， 康方生物 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。此外，国信证券发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":320190642696248,"gmtCreate":1719201566969,"gmtModify":1719202791986,"author":{"id":"4094165147073770","authorId":"4094165147073770","authorIdStr":"4094165147073770","name":"慧敏儿","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/320190642696248","repostId":"1114706690","repostType":2,"repost":{"id":"1114706690","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1719194593,"share":"https://www.laohu8.com/m/news/1114706690?lang=&edition=full","pubTime":"2024-06-24 10:03","market":"hk","language":"zh","title":"港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保","url":"https://stock-news.laohu8.com/highlight/detail?id=1114706690","media":"老虎资讯综合","summary":"6月24日， 康方生物逆市涨超4%，截至发稿，涨3.93%，报37.05港元。","content":"<html><head></head><body><p>6月24日， <a href=\"https://laohu8.com/S/09926\">康方生物</a> 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fad0d39ba4732de4e269b59b1699349\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。</p><p style=\"text-align: start;\">此外，<a href=\"https://laohu8.com/S/002736\" title=\"国信证券\" class=\"\">国信证券</a>发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-06-24 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>6月24日， <a href=\"https://laohu8.com/S/09926\">康方生物</a> 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fad0d39ba4732de4e269b59b1699349\" tg-width=\"560\" tg-height=\"240\"/></p><p style=\"text-align: start;\">消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。</p><p style=\"text-align: start;\">此外，<a href=\"https://laohu8.com/S/002736\" title=\"国信证券\" class=\"\">国信证券</a>发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"09926":"康方生物"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114706690","content_text":"6月24日， 康方生物 逆市涨超4%，截至发稿，涨3.93%，报37.05港元。消息面上，据科创板日报报道，近日市场流传的卡度尼利降价消息为真，而降价前的赠药方案在降价后一并取消。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。此外，国信证券发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。中金则表示，依沃西单抗国内获批、K药头对头成功，建议关注公司产品商业化和海外临床进展带来的弹性空间。","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
